This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IDEXX (IDXX) Q3 Earnings Beat Estimates, 2022 EPS View Down
by Zacks Equity Research
IDEXX's (IDXX) Q3 top-line performance rides on strong CAG Diagnostics recurring revenue growth.
Stryker's (SYK) Q3 Earnings Miss Estimates, Volume Improves
by Zacks Equity Research
Stryker's (SYK) third-quarter earnings reflect strong performance across its segments. However, unfavorable currency movement hurt sales growth.
Ecolab (ECL) Q3 Earnings & Revenues Miss Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across all its segments drives its Q3 sales, despite business challenges.
Henry Schein (HSIC) Q3 Earnings In Line, 2022 Sales View Down
by Zacks Equity Research
Severe currency headwinds and lower sales of PPE and COVID-19 test kits affect Henry Schein's (HSIC) top line in Q3.
Teleflex (TFX) Q3 Earnings Top Estimates, Adjusted EPS View Cut
by Zacks Equity Research
For UroLift, Teleflex (TFX) currently assumes 2022 revenues to be roughly $320 million, down from the prior guidance of $335 million.
Abiomed (ABMD) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Medpace (MEDP) and Ensign Group (ENSG) have performed compared to their sector so far this year.
ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls
by Zacks Equity Research
ResMed (RMD) continues to increase its access to semiconductor communications chips.
Amedisys (AMED) Q3 Earnings Miss Estimates, Guidance Cut
by Zacks Equity Research
Within Amedisys (AMED) Home Health and Hospice, the reinstatement of sequestration reduces growth in Q3.
Avantor (AVTR) Q3 Earnings Top Estimates, 2022 EPS View Cut
by Zacks Equity Research
Avantor's (AVTR) robust performance across the majority of its segments drives its Q3 sales, despite business challenges.
Edwards Lifesciences (EW) Q3 Earnings Miss, Margins Rise
by Zacks Equity Research
Edwards Lifesciences (EW) continues to register strong momentum in TMTT on a portfolio of differentiated therapies, positive pivotal trial results and favorable real-world clinical outcomes.
Bio-Rad (BIO) Q3 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Bio-Rad's (BIO) third-quarter revenues decline mainly as a result of lower COVID-related sales compared with the year-ago period.
DexCom (DXCM) Q3 Earnings Beat Estimates, Guidance Revised
by Zacks Equity Research
DexCom's (DXCM) third-quarter results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
Integer Holdings (ITGR) Q3 Earnings Beat, 2022 View Lowered
by Zacks Equity Research
Integer Holdings' (ITGR) third-quarter results reflect robust Medical and Non-Medical Sales, besides strength in all the product lines.
DaVita (DVA) Q3 Earnings Lag Estimates, 2022 EPS View Cut
by Zacks Equity Research
DaVita's (DVA) Q3 performance gets a boost from strength in both its segments.
Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M
by Zacks Equity Research
Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.
LabCorp (LH) Misses Q3 Earnings Estimates, Updates Guidance
by Zacks Equity Research
LabCorp's (LH) organic revenues decline significantly, mainly due to major decrease in COVID-19 PCR and antibody testing sales.
Merit Medical (MMSI) Q3 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the third quarter, benefits from revenue growth in both its segments and the majority of product categories within its Cardiovascular unit.
Integra's (IART) Q3 Earnings Top, Gross Margin Declines
by Zacks Equity Research
Integra (IART) notices recovery in procedure volumes leading to solid growth across most of its product portfolio in Q3.
Align Technology (ALGN) Q3 Earnings Lag Estimates, Margins Drop
by Zacks Equity Research
The volatility surrounding inflationary pressure, weaker consumer confidence and the lingering impacts of COVID-19 shutdowns continue to pose challenges for Align Technology (ALGN).
CONMED (CNMD) Down on In-Line Q3 Earnings & Lower 2022 View
by Zacks Equity Research
CONMED's (CNMD) adjusted third-quarter earnings reflect strong segmental performance. Unfavorable currency movement hurt sales growth. Inflationary or supply chain challenges hurt gross margin.
Medpace Holdings, Inc. (MEDP) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
West Pharmaceutical (WST) Q3 Earnings Miss, FY22 View Revised
by Zacks Equity Research
West Pharmaceutical's (WST) third-quarter results reflect sustained growth in non-COVID-19 demand amid dismal overall performance.
Medpace (MEDP) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Medpace (MEDP) could produce exceptional returns because of its solid growth attributes.
Thermo Fisher (TMO) Q3 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Robust demand for Thermo Fisher's (TMO) laboratory products and biopharma services buoys optimism. However, lower Life Sciences Solutions segment revenues in the third quarter disappoint.